Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Slides:

Advertisements

Similar presentations

Figure 2 Response after initial increase in total tumour burden

Advertisements

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Prognostic significance of DDB2 in ovarian cancer.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

Streptavidin identified in the vaccine protein profiles.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Clinical benefit from combination limb infusion and CTLA-4 blockade.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Uptake of TEX by DCs in vivo.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Intratumoral tertiary lymphoid aggregates observed in PDACs from Panc GVAX–treated patients. Intratumoral tertiary lymphoid aggregates observed in PDACs.

Duration of treatment and intervals of radiographic and ctDNA response

Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Mass spectrometry identification.

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Intratumoral lymphoid aggregates are sites of postvaccination T-cell activation and regulation. Intratumoral lymphoid aggregates are sites of postvaccination.

Influenza vaccine enhances NK cell function through IFN-α.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

MDC/CCL22 and MMP-2 factors are found in the melanoma microenvironment and correlate with pDC accumulation and early relapse. MDC/CCL22 and MMP-2 factors.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

PD-1 expression in ovarian cancer.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Location of the ER mutations and frequencies per cohort.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Change in FES uptake in the tumor during fulvestrant treatment.

CPI-444 enhances T-cell activation in MC38 tumors.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Genomic determinants of response to cytotoxic chemotherapy.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Impact of IFNγ in B16 melanoma metastasis.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Progression and survival analysis.

Survival, subsequent therapies, and response.

Biopsies of the vaccination site were obtained 48 h after the first vaccination. Biopsies of the vaccination site were obtained 48 h after the first vaccination.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Immunohistochemical determination of TIM-3 expression in ccRCC.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

MDSC population in patient peripheral blood.

Schematic presentation of the major domains of Alps, the signal peptide (S), the N-terminal region (N), the repeat region (R), and the C-terminal region.

CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment.

Presentation transcript:

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Ten of the 92 patients in cohorts 4–6 and 2 of those in cohort 5 progressed before week 12, which precluded collection of their post-treatment data. A, patients in cohorts 4–6 who were refractory to ipilimumab and received nivolumab. The transition point is indicated by the arrow at 63%. B, cohort 5's 19 patients who were refractory to ipilimumab, and who experienced grade 3–4 irAEs after treatment with ipilimumab. Jeffrey Weber et al. Cancer Immunol Res 2016;4:345-353 ©2016 by American Association for Cancer Research